Linköping Sweden, Shanghai China – November 6, 2024. LinkoCare Life Sciences AB announced that it had completed a new fundraising round this year and product out-licensing its product to a Chinese strategic investor. LinkoCare is a Swedish knowledge-intensive bioengineering company developing innovative medical devices for sight restoration. The company’s vision is to provide society with natural, high-quality, reliable, cost-effective bio-engineered corneal implants that meet the huge demand of the world population suffering from corneal blindness and low vision. LinkoCare corneal implants can be used both for patients with corneal blindness who need a full-thickness implant and for those who suffer from corneal vision impairment and need a partial-thickness implant. LinkoCare bio-engineered implants will capture a significant share of the market for corneal blindness and low vision due to their advanced functionality, safety, cost-effectiveness, and long-term durability over existing solutions such as human donor corneas, the prosthetic artificial corneas, and synthetic inter-corneal lenses.

Dr. Mehrdad Rafat, Founder and CEO of LinkoCare, commented, “We are thrilled to continue our collaboration with Collabrium Partners to complete a new round of financing and license out our product pipelines. This will enable us to complete the construction of new production facilities and product registration activities. Additionally, we are honored to license our products to a reliable partner in China, further accelerating the commercialization of our products in China and benefiting Chinese patients.”

Adam Zhang, Founding Partner and CEO of Collabrium Partners, further commented, “We are delighted to continue offering advisory services for LinkoCare's recent financing and product licensing activities in China. This reflects our robust network and expertise in the global healthcare and technology sectors, as well as our commitment to long-term service.”

About LinkoCare

LinkoCare is a company headquartered in Linköping, Sweden, which was founded in 2014 and originated from academic research in Canada and Sweden. The company has developed two major platforms, CorVision® and LinkCor®. CorVision® is a natural corneal microlens made of collagen, the same material as the human cornea. The microlens integrate with the corneal environment long-term and avoid biocompatibility, haze, and interface issues associated with other microlenses. It eliminates the need for reading spectacles, contact lenses, or more invasive surgeries such as LASIK. LinkCor® is a bioengineered corneal implant for the treatment of corneal blindness caused by diseases such as keratoconus, corneal dystrophy, and corneal scarring. Partial thickness inter-corneal implants are also available for sight correction in patients with low vision.